Kensey Nash seeks FDA OK to market QuickCat extraction catheter

By Angela McDaniels

Seattle, Jan. 12 - Kensey Nash Corp. said it has submitted a Premarket Notification to the Food and Drug Administration requesting permission to market its QuickCat Extraction Catheter.

The QuickCat is a fully disposable catheter system that uses aspiration to quickly draw a soft blood clot out of the body.

"We are endeavoring to offer our physician customers with a full product line of embolic protection and thrombus extraction products," president and chief executive officer Joseph W. Kaufmann said in a company news release.

"By the end of our fiscal year, we are expecting to offer the new TriActiv FX Embolic Protection System, the ThromCat Thrombectomy Catheter System and now the QuickCat Extraction Catheter.

"In addition, we expect to complete our pilot trials on our TriActiv ProGuard Embolic Protection System in the carotid anatomy, which will be followed by the commencement of a larger pivotal trial for carotid embolic protection."

The QuickCat will be sold through Kensey Nash's direct U.S. endovascular sales force. The company estimated the current market for thrombectomy catheter systems to be $100 million worldwide.

Kensey Nash is based in Exton, Pa., and develops and manufactures absorbable, biomaterial-based products with applications in the cardiology, orthopaedics, spine, drug and biologics delivery, dental, surgical and wound care markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.